LARGE-SCALE CLINICAL AND POPULATION-BASED RESEARCH
Professor Christopher Reid,
Cardiovascular Epidemiologist & Research Professor, School of Public Health & Preventive Medicine, Monash University, Victoria, Australia & School of Population Health at Curtin University, Western Australia & Chair, Australian Clinical Trials Alliance (ACTA)
RESEARCHER PROFILE
Filmed in Perth, Australia | October 2026
Christopher Reid is an internationally renowned cardiovascular epidemiologist with appointments as a Research Professor in both the School of Population Health at Curtin University and the School of Public Health and Preventive Medicine, at Monash University.
He was re-appointed as a John Curtin Distinguished Professor in 2021 and is currently Director of the Monash and Curtin Centre for Clinical Research and Education (CCRE). He has been awarded over $178M as a Chief Investigator and has received continuous NHMRC funding since 2001.
His major research interests include clinical outcome registries, randomised controlled trials, and epidemiological cohort studies. He has over 820 peer-reviewed publications (with over 44000 citations and a H-Index of 91) many of which are in leading journals including the New England Journal of Medicine, the Lancet, JAMA, JACC, and the BMJ.
He is a Chief Investigator for the Colchicine in Type 2 diabetes trial (COLCOT-T2D), the Aspirin in the Elderly (ASPREE) trial, the HOPE-3 trial, the Statins in Reducing Events in the Elderly (STAREE) trial and the LEADER-PAD trial. He is also the research director for the Australian and New Zealand Cardiothoracic database (ANZSCTS) registry and the Victorian Cardiac Outcomes registry (VCOR).
He is the Board Chair of the Australian Clinical Trials Alliance (ACTA) and a board member of the Australian New Zealand Alliance for Cardiovascular Trials (ANZACT) Network and the Australian Cardiovascular Alliance (ACVA).
Prof Reid has trained more than 30 PhD students to completion and undertaken assignments for the World Health Organization in cardiovascular disease prevention in the Asia Pacific Region.
Source: Supplied
https://orcid.org/0000-0001-9173-3944
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
